George Karpouzas

Dr. George Karpouzas


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
ZSZoltán Szekanecz
Zoltán Szekanecz
MBMaya H. Buch
Maya H. Buch
CCChristina Charles-Schoeman
Christina Charles-Schoeman
JGJames Galloway
James Galloway
GKGeorge Karpouzas
George Karpouzas
RFRoy Fleischmann
Roy Fleischmann

21 April 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGeorge Karpouzas
George Karpouzas
SOSarah R. Ormseth
Sarah R. Ormseth
EHElizabeth Hernandez
Elizabeth Hernandez
MBMatthew J. Budoff
Matthew J. Budoff

18 September 2019 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGeorge Karpouzas
George Karpouzas
SOSarah R. Ormseth
Sarah R. Ormseth
EHElizabeth Hernandez
Elizabeth Hernandez
MBMatthew J. Budoff
Matthew J. Budoff

28 November 2019 in Rheumatology
Verified
Journal Article
Open access
IRIda K Roelsgaard
Ida K Roelsgaard
EIEirik Ikdahl
Eirik Ikdahl
SRSilvia Rollefstad
Silvia Rollefstad
GWGrunde Wibetoe
Grunde Wibetoe
BEBente A Esbensen
Bente A Esbensen
ASAnne Grete Semb
Anne Grete Semb
Objectives: Smoking is a major risk factor for the development of both cardiovascular disease (CVD) and RA and may cause attenuated responses to anti-rheumatic treatments. Our aim was to compare disease activity, CVD risk factors and CVD event rates across smoking status in RA patients. Methods: Disease characteristics, CVD risk factors and relevant medications were recorded in RA patients without prior CVD from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico). Information on CVD events was collected. Adjusted analysis of variance, logistic regression and Cox models were applied to compare RA disease activity (DAS28), CVD risk factors and event rates across categories of smoking status. Results: Of the 3311 RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced CVD events during a median follow-up of 3.5 years (interquartile range 2.5–6.1). At enrolment, current smokers were more likely to have moderate or high disease activity compared with former and never smokers (P < 0.001 for both). There was a gradient of worsening CVD risk factor profiles (lipoproteins and blood pressure) from never to former to current smokers. Furthermore, former and never smokers had significantly lower CVD event rates compared with current smokers [hazard ratio 0.70 (95% CI 0.51, 0.95), P = 0.02 and 0.48 (0.34, 0.69), P < 0.001, respectively]. The CVD event rates for former and never smokers were comparable. Conclusion: Smoking cessation in patients with RA was associated with lower disease activity and improved lipid profiles and was a predictor of reduced rates of CVD events.

5 April 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
GKGeorge Karpouzas
George Karpouzas
SDSoha Dolatabadi
Soha Dolatabadi
RMRosalinda Moran
Rosalinda Moran
NLNing Li
Ning Li
PNPerry M. Nicassio
Perry M. Nicassio
MWMichael H. Weisman
Michael H. Weisman
Objective: US Hispanics with rheumatoid arthritis experience worse functional outcomes compared to whites. The determinants of disability, however, are not well established in large Hispanic cohorts. In the present report, we identified factors associated with disability in a cross‐sectional design, and evaluated their individual contributions to disability over time.Methods: Two hundred fifty‐one Hispanic subjects from a single center were evaluated. Disease activity, serologies, radiographs, treatments, irreversible articular damage (defined as subluxation, arthrodesis, fusion, or prosthesis), and joint replacement surgeries were recorded. Self‐reported disability (Health Assessment Questionnaire disability index), patient pain by a visual analog scale, and depression assessments were collected. Cross‐sectional factors associated with disability were identified, and their effects on future disability were evaluated in a subgroup of 114 patients assessed 6 months later.Results: Six parameters were independently related to disability cross‐sectionally: pain was the strongest (P < 0.0001), followed by irreversible articular damage, disease activity, depression, age, and fibromyalgia (P < 0.03 for all). Baseline parameters predicting disability 6 months later included, in decreasing significance, irreversible articular damage (P = 0.004), depression, disease activity, age, and pain (all P < 0.04).Conclusion: In cross‐sectional analysis, self‐reported pain had the strongest relationship with disability; however, factors such as irreversible articular damage, depression, and disease activity were more important in predicting future disability. Most of these factors are amenable to targeted interventions and should be addressed in an effort to improve functional outcomes.

14 March 2018 in Rheumatology
Verified
Journal Article
Closed access
PDF file
GKGeorge Karpouzas
George Karpouzas
JEJoel Estis
Joel Estis
PRPanteha Rezaeian
Panteha Rezaeian
JTJohn Todd
John Todd
MBMatthew J Budoff
Matthew J Budoff
Patients with RA display greater occult coronary atherosclerosis burden and experience higher cardiovascular morbidity and mortality compared with controls. We here explored whether pro-inflammatory cytokines and high-sensitivity cardiac troponin I (hs-cTnI), a biomarker of myocardial injury, correlated with plaque burden and cardiovascular events (CVEs) in RA. We evaluated 150 patients with 64-slice coronary CT angiography. Coronary artery calcium, number of segments with plaque (segment involvement score), stenotic severity and plaque burden were assessed. Lesions were described as non-calcified, mixed or fully calcified. Blood levels of hs-cTnI and pro-inflammatory cytokines were assessed during coronary CT angiography. Subjects were followed over 60 (s.d. 26) months for both ischaemic [cardiac death, non-fatal myocardial infarction (MI), stroke, peripheral arterial ischaemia] and non-ischaemic (new-onset heart failure hospitalization) CVEs. Plasma hs-cTnI correlated with all coronary plaque outcomes (P < 0.01). Elevated hs-cTnI (⩾1.5 pg/ml) further associated with significant calcification, extensive atherosclerosis, obstructive plaque and any advanced mixed or calcified plaques after adjustments for cardiac risk factors or Framingham D’Agostino scores (all P < 0.05). Eleven patients suffered a CVE (1.54/100 patient-years), eight ischaemic and three non-ischaemic. Elevated hs-cTnI predicted all CVE risk independent of demographics, cardiac risk factors and prednisone use (P = 0.03). Conversely, low hs-cTnI presaged a lower risk for both extensive atherosclerosis (P < 0.05) and incident CVEs (P = 0.037). Plasma hs-cTnI independently associated with occult coronary plaque burden, composition and long-term incident CVEs in patients with RA. Low hs-cTnI forecasted a lower risk for both extensive atherosclerosis as well as CVEs. hs-cTnI may therefore optimize cardiovascular risk stratification in RA.